Bipolar Therapeutics Update 2014: A Tale of 3 Treatments

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

In the 2010s, advances in the treatment of bipolar disorder slowed, with only 1 agent approved by the US Food and Drug Administration (FDA) for acute bipolar I depression (in 2013), compared to the robust progress in the 2000s, during which 7 agents were approved for acute mania, 2 for acute bipolar depression, and 6 for bipolar disorder preventive treatment. This slowing of progress may have been in part due to decreased pharmaceutical company enthusiasm for developing compounds for psychiatric indications, as well as the tendency for periods of consolidation (development of derivative and better-tolerated treatments) to follow periods of rapid advances (development of efficacious novel treatments) in pharmacotherapy advancement.

J Clin Psychiatry 2015;76(1):69–70

https://doi.org/10.4088/JCP.14ac09649